a rapid new wave of innovations in technologies and therapies in oncology continue to disrupt the landscape, and while these innovations have the potential to transform the way cancer is diagnosed, treated and managed- payors, decision makers, manufacturers and care providers must address the hurdles to access to deliver on the promise of these new innovations.
navigating the increasing maze of cancer treatment options, addressing affordability, and ensuring excellent care remains a complex challenge. concerns about these issues go hand in hand with the growing excitement about new treatments. how do we manage innovation in oncology when funding unlimited treatment choices is increasingly unsustainable but the need to create a value paradigm for cancer care is of upmost importance?
identifying priority areas in managing innovation, including new approaches to both cancer policies and cancer care delivery issues will be vital to ensure that innovations in research, diagnosis and treatment meant to improve patient outcomes without increasing disparities must be meet with innovation on how cancer care is organized and delivered.
as the environment shifts to more personalized medicine models and value based, greater requirements to demonstrate this value and improved outcomes will be necessary as questions of affordability will continue to dominate conversations. how can we fund innovation tomorrow with sustainability issues of today?
what are the opportunities created by this new wave of innovation? what are the barriers created by this new wave of innovation? how can we mitigate these barriers and challenges in a way that makes sense for all the stakeholders? how can we capitalize and drive innovation and investment in innovation-while continuing to provide high quality cancer care in canada in a sustainable manner? what challenges need to be resolved in order to positively affect the practice of oncology at scale? what will oncology look like in 2025? what challenges and opportunities will need to be overcome in the next 2,5,7 years? will first dollar rebate drive[or hinder] innovation decisions or will value dominate the conversations?
decisions taken today will have an impact for cancer patients and healthcare systems over the next decade and manufacturers, regulators and health care providers must address a number of hurdles including clinical, regulatory and market access.
implementing innovation driven, value-based outcomes requires us to start having these conversations today at the provincial, national and global level, so that we can prepare for the future of cancer care, taking into consideration the complexities, challenges, and opportunities that innovation provides us and address these barriers to fundamentally manage innovation in oncology.